AAAAAA

   
Results: 1-6 |
Results: 6

Authors: McCormack, RT Southwick, PC
Citation: Rt. Mccormack et Pc. Southwick, Informed consent in clinical trials of in vitro diagnostic devices: Perspectives from the FDA and manufacturers - A perspective from manufacturers, CLIN CHEM, 47(10), 2001, pp. 1755-1757

Authors: Southwick, PC
Citation: Pc. Southwick, The role of free PSA in the detection of prostate cancer, LAB MED, 32(5), 2001, pp. 259-263

Authors: Catalona, WJ Southwick, PC Slawin, KM Partin, AW Brawer, MK Flanigan, RC Patel, A Richie, JP Walsh, PC Scardino, PT Lange, PH Gasior, GH Loveland, KG Bray, KR
Citation: Wj. Catalona et al., Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, UROLOGY, 56(2), 2000, pp. 255-260

Authors: Catalona, WJ Partin, AW Slawin, KM Naughton, CK Brawer, MK Flanigan, RC Richie, JP Patel, A Walsh, PC Scardino, PT Lange, PH deKernion, JB Southwick, PC Loveland, KG Parson, RE Gasior, GH
Citation: Wj. Catalona et al., Percentage of free PSA in black versus white men for detection and stagingof prostate cancer: A prospective multicenter clinical trial, UROLOGY, 55(3), 2000, pp. 372-376

Authors: Southwick, PC Catalona, WJ Partin, AW Slawin, KM Brawer, MK Flanigan, RC Patel, A Richie, JP Walsh, PC Scardino, PT Lange, PH Gasior, GH Parson, RE Loveland, KG
Citation: Pc. Southwick et al., Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial, J UROL, 162(4), 1999, pp. 1346-1351

Authors: Chan, DW Kelley, CA Ratliff, TL D'Agostino, D Ritchey, J Lamb, DJ Beck, J Lott, N Wener, MH Daum, P Henkin, RE Kaske, DN Golightly, DW McBride, J Layco, G Ota, MK Tanasijevic, MJ Grudzien, C Woodrum, DL Bray, KR Southwick, PC Gasior, GH Loveland, KG
Citation: Dw. Chan et al., Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine theclinical utility of percentage of free prostate-specific antigen, CLIN CHEM, 45(10), 1999, pp. 1863-1865
Risultati: 1-6 |